Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers

Journal of Carcinogenesis

Volumn 10, Issue , 2011, Pages

  Almubarak, Hussain ^a   Jones, Antonia ^a   Chaisuparat, Risa ^b   Zhang, Ming ^a   Meiller, Timothy F ^a   Scheper, Mark A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Apoptosis; bisphosphonate; cancer; metastasis; zoledronic acid

Indexed keywords

CASPASE 2; CASPASE 3; CASPASE 7; CASPASE 9; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; SURVIVIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 79960338131     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.75723     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032-45.
3. Lyseng-Williamson KA. Zoledronic acid: A review of its use in breast cancer. Drugs 2008;68:2661-82.
4. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004;8:1-176.
5. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;3:CD003474.
6. Brown HK, Holen I. Anti-tumour effects of bisphosphonates: What have we learned from in vivo models? Curr Cancer Drug Targets 2009;9:807-23.
7. Freedman OC, Amir E, Clemons MJ. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction? Crit Rev Oncol Hematol 2009;72:56-64.
8. Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007;246:308-12. (Pubitemid 44959401)
9. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010;11:141-54.
10. Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, et al. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets 2010;10:46-54.
11. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22:195-201. (Pubitemid 41003454)
12. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24:227-30. (Pubitemid 350135975)
13. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH Jr, Ravera C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003;43:154-62. (Pubitemid 36125942)
14. Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol 2003;170:S55-57; discussion S57-58.
15. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004;94:164-70. (Pubitemid 38980328)
16. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105.
17. Clyburn RD, Reid P, Evans CA, Lefley DV, Holen I. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 2010;65:969-78.
18. Bruce Alberts AJ, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell. 4th ed. Garland Science; 2002.
19. Nakajima H, Magae J, Tsuruga M, Sakaguchi K, Fujiwara I, Mizuta M, et al. Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529: A new third generation bisphosphonate. Cancer Lett 2007;253:89-96. (Pubitemid 46874729)
20. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-90. (Pubitemid 39372048)
21. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci 2008;99:1709-14.
22. Zohny SF, El-Shinawi M. Significance of survivin and Bcl-2 homologous antagonist/Killer mRNA in detection of bone metastasis in patients with breast cancer. Med Oncol 2010 in press.
23. Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiate Oncol Biol Phys 2010;78:1095-103.
24. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: Pre-clinical studies. Apoptosome, biomedical and life sciences, USA: Springer Science, 2010. p. 147-68.
25. Ryan BM, O'Donovan N, Duffy MJ. Survivin: A new target for anti-cancer therapy. Cancer Treatment Rev 2010;35:553-62.